The New England journal of medicine
-
Editorial Comment
Treatment by CRISPR-Cas9 Gene Editing - A Proof of Principle.
-
Randomized Controlled Trial Multicenter Study
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
Recent data suggest that complications and death from coronavirus disease 2019 (Covid-19) may be related to high viral loads. ⋯ In this interim analysis, the REGN-COV2 antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline. Safety outcomes were similar in the combined REGN-COV2 dose groups and the placebo group. (Funded by Regeneron Pharmaceuticals and the Biomedical and Advanced Research and Development Authority of the Department of Health and Human Services; ClinicalTrials.gov number, NCT04425629.).
-
Randomized Controlled Trial Multicenter Study
Polypill with or without Aspirin in Persons without Cardiovascular Disease.
A polypill comprising statins, multiple blood-pressure-lowering drugs, and aspirin has been proposed to reduce the risk of cardiovascular disease. ⋯ Combined treatment with a polypill plus aspirin led to a lower incidence of cardiovascular events than did placebo among participants without cardiovascular disease who were at intermediate cardiovascular risk. (Funded by the Wellcome Trust and others; TIPS-3 ClinicalTrials.gov number, NCT01646437.).